A Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancers with DDR2 or Inactivating BRAF Mutations
[Protocol 12-163] |
Paik, Paul |
- Lung Cancer
- Lung Cancer, Non-Small Cell
|
A Phase II Study of DN24-02 as Adjuvant Therapy in Patients with High-Risk HER2-positive Urothelial Cancers
[Protocol 11-163] |
Bajorin, Dean |
|
A Phase II Study of Docosahexaenoic Acid (DHA) in Survivors of Triple-Negative Breast Cancer
[Protocol 12-267] |
Hudis, Clifford |
- Breast Cancer
- Survivorship
|
A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
[Protocol 13-022] |
Noy, Ariela |
|
A Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide followed by Eribulin Mesylate for the Adjuvant Treatment of Early-Stage Breast Cancer
[Protocol 10-190] |
Traina, Tiffany |
|
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low- Grade and Anaplastic Ependymoma
[Protocol 09-031] |
Omuro, Antonio |
- Brain Tumors, Primary
- Pediatric Brain Tumors
|
A Phase II Study of Everolimus as Second-Line Therapy in the Treatment of Metastatic Renal Cell Carcinoma
[Protocol 11-197] |
Motzer, Robert |
|
A Phase II Study of Everolimus, Leuprolide/Letrozole, and Everolimus/Leuprolide/Letrozole in Patients with Inoperable Fibrolamellar Hepatocellular Carcinoma
[Protocol 11-211] |
Abou-Alfa, Ghassan |
|
A Phase II Study of Fulvestrant Alone or with GDC-0941 or GDC-0980 in Women with Advanced Breast Cancer Resistant to Aromatase Inhibitor Therapy
[Protocol 12-029] |
Dickler, Maura |
|
A Phase II Study of GC33 in Patients with Advanced Hepatocellular Carcinoma
[Protocol 12-145] |
Abou-Alfa, Ghassan |
|
A Phase II Study of Gemcitabine and Cisplatin before Surgery in Patients with High-Grade Upper Tract Urothelial Carcinoma
[Protocol 10-208] |
Coleman, Jonathan |
|
A Phase II Study of Gemcitabine and Pazopanib in Previously Untreated Patients with Advanced Urothelial Cancers Who Cannot Receive Cisplatin
[Protocol 11-191] |
Bajorin, Dean |
- Bladder Cancer
- Kidney Cancer
|
A Phase II Study of GSK2118436 in Patients with Advanced Non-Small Cell Lung Cancer and BRAF Mutations
[Protocol 11-023] |
Riely, Gregory |
- Lung Cancer
- Lung Cancer, Non-Small Cell
|
A Phase II Study of Hepatic Arterial Infusion and Intravenous Chemotherapy with or without Panitumumab in Patients with Normal KRAS with Resected Liver Metastases from Colorectal Cancer
[Protocol 10-137] |
Kemeny, Nancy |
|
A Phase II Study of High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission after Non-Myeloablative Therapy in Patients with High-Risk Neuroblastoma
[Protocol 09-159] |
Kushner, Brian |
|
A Phase II Study of High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
[Protocol 09-160] |
Kushner, Brian |
|
A Phase II Study of High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in the Bone Marrow
[Protocol 09-161] |
Kushner, Brian |
|
A Phase II Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
[Protocol 12-205] |
Chou, Alexander |
|
A Phase II Study of Intrathecal I131-3F8 in Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
[Protocol 05-122] |
Kramer, Kim |
- Brain Tumors, Metastatic
- Brain Tumors, Primary
- Neuroblastoma
- Pediatric Brain Tumors
|
A Phase II Study of Ipilimumab after Completion of Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian Cancer with Measurable Residual Disease
[Protocol 12-152] |
Grisham, Rachel |
|
